NZ590885A - A modified release pharmaceutical formulation of retigabine for the treatment of nervous system hyperexcitability - Google Patents

A modified release pharmaceutical formulation of retigabine for the treatment of nervous system hyperexcitability

Info

Publication number
NZ590885A
NZ590885A NZ590885A NZ59088509A NZ590885A NZ 590885 A NZ590885 A NZ 590885A NZ 590885 A NZ590885 A NZ 590885A NZ 59088509 A NZ59088509 A NZ 59088509A NZ 590885 A NZ590885 A NZ 590885A
Authority
NZ
New Zealand
Prior art keywords
retigabine
pharmaceutical formulation
nervous system
modified release
treatment
Prior art date
Application number
NZ590885A
Other languages
English (en)
Inventor
Biljana Nadjsombati
Original Assignee
Valeant Pharmaceuticals Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41550741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ590885(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valeant Pharmaceuticals Int filed Critical Valeant Pharmaceuticals Int
Publication of NZ590885A publication Critical patent/NZ590885A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ590885A 2008-07-18 2009-07-17 A modified release pharmaceutical formulation of retigabine for the treatment of nervous system hyperexcitability NZ590885A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8216208P 2008-07-18 2008-07-18
PCT/US2009/051052 WO2010009433A1 (en) 2008-07-18 2009-07-17 Modified release formulation and methods of use

Publications (1)

Publication Number Publication Date
NZ590885A true NZ590885A (en) 2013-01-25

Family

ID=41550741

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ590885A NZ590885A (en) 2008-07-18 2009-07-17 A modified release pharmaceutical formulation of retigabine for the treatment of nervous system hyperexcitability

Country Status (16)

Country Link
US (1) US20100120906A1 (enExample)
EP (1) EP2318001A4 (enExample)
JP (1) JP2011528666A (enExample)
KR (1) KR20110052641A (enExample)
CN (1) CN102170879B (enExample)
AU (1) AU2009270768A1 (enExample)
BR (1) BRPI0916000A2 (enExample)
CA (1) CA2731008A1 (enExample)
CL (1) CL2011000109A1 (enExample)
CO (1) CO6351716A2 (enExample)
EA (1) EA201170230A1 (enExample)
IL (1) IL210683A0 (enExample)
MX (1) MX2011000636A (enExample)
NZ (1) NZ590885A (enExample)
WO (1) WO2010009433A1 (enExample)
ZA (1) ZA201102518B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009013613A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
DE102009013612A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
BR112012010201A2 (pt) 2009-11-03 2017-08-08 Lupin Ltd formulação de libertação modificada da lacosamida
SG181827A1 (en) 2010-01-20 2012-07-30 Glaxo Group Ltd Novel retigabine composition
BR112012018173A2 (pt) * 2010-01-20 2017-08-29 Valeant Pharmaceuticals Int "formulação de liberação modificada e método de uso"
JP2014510714A (ja) 2011-01-18 2014-05-01 グラクソ グループ リミテッド レチガビンの製造方法
CA3207643A1 (en) 2015-09-23 2017-03-30 XWPharma Ltd. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物
WO2021113381A1 (en) * 2019-12-02 2021-06-10 Xenon Pharmaceuticals Inc. Pediatric immediate-release formulation of the potassium channel opener ezogabine

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) * 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
JP2000086509A (ja) * 1998-09-14 2000-03-28 Taisho Yakuhin Kogyo Kk ソファルコン含有製剤の製造方法
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
JP2003506388A (ja) * 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド 疼痛および不安症を処置または予防するための方法
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
PL202935B1 (pl) * 2000-03-08 2009-08-31 Awd Pharma Gmbh & Co Kg Doustny preparat farmaceutyczny o zmiennie nastawianej charakterystyce uwalniania oraz sposób wytwarzania takiego preparatu
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
GB0027471D0 (en) * 2000-11-08 2000-12-27 Smithkline Beecham Plc Processes
AU2256702A (en) * 2000-12-01 2002-06-11 Kyowa Hakko Kogyo Kk Composition improved in solubility or oral absorbability
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
AR033095A1 (es) * 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
KR100425226B1 (ko) * 2001-07-03 2004-03-30 주식회사 팜트리 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법
GB0120835D0 (en) * 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
SE0103369D0 (sv) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1524981B1 (en) * 2002-07-29 2009-03-11 Glaxo Group Limited Sustained release formulations comprising lamotrigine
KR20050084559A (ko) * 2002-09-17 2005-08-26 와이어쓰 경구 제형
JP2004131393A (ja) * 2002-10-08 2004-04-30 Kowa Co 易溶出性製剤
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
US20070259033A1 (en) * 2003-09-26 2007-11-08 Evangeline Cruz Controlled release formulations exhibiting an ascending rate of release
GB0324574D0 (en) * 2003-10-21 2003-11-26 Glaxo Group Ltd Novel compositions
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
WO2006044202A2 (en) * 2004-10-19 2006-04-27 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
GB0502475D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
WO2007034503A2 (en) * 2005-06-20 2007-03-29 Cadila Healthcare Limited Controlled release dosage formulation of duloxetine
JP5543110B2 (ja) * 2006-01-05 2014-07-09 エッセンシャリス，インク． カリウムａｔｐチャネルオープナの塩およびその使用
US8558470B2 (en) * 2006-01-20 2013-10-15 Point Somee Limited Liability Company Adaptive current regulation for solid state lighting
USD601689S1 (en) * 2006-05-12 2009-10-06 Glaxo Group Limited Pharmaceutical tablet
BRPI0719590A2 (pt) * 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio

Also Published As

Publication number Publication date
WO2010009433A1 (en) 2010-01-21
CN102170879B (zh) 2014-03-05
CN102170879A (zh) 2011-08-31
CO6351716A2 (es) 2011-12-20
AU2009270768A1 (en) 2010-01-21
IL210683A0 (en) 2011-03-31
CA2731008A1 (en) 2010-01-21
ZA201102518B (en) 2012-06-27
EP2318001A4 (en) 2013-02-20
US20100120906A1 (en) 2010-05-13
EP2318001A1 (en) 2011-05-11
JP2011528666A (ja) 2011-11-24
MX2011000636A (es) 2011-08-03
BRPI0916000A2 (pt) 2019-09-24
EA201170230A1 (ru) 2011-08-30
CL2011000109A1 (es) 2011-11-25
KR20110052641A (ko) 2011-05-18

Similar Documents

Publication Publication Date Title
NZ590885A (en) A modified release pharmaceutical formulation of retigabine for the treatment of nervous system hyperexcitability
CA2787907A1 (en) Modified release formulation and methods of use
AU2010209790B2 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
US10729653B2 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
BR112013004443A8 (pt) composições farmacêuticas de (r)-1-(2,2-difluorbenzo[d] [1,3]dioxol-5-il)-n-(1-(2,3-di-hidróxipropil)-6-flúor-2-(1-hidróxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropano carboxamida e administração das mesmas
MX2011008448A (es) Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
EA201071035A1 (ru) Фармацевтические композиции модифицированного высвобождения, содержащие микофенолат, и способ их получения
PH12021551635A1 (en) Hexone glucokinase inhibitor and use thereof
AR092857A1 (es) Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
JP2012514624A5 (enExample)
TNSN08348A1 (en) Antibiotic compositions of modified release and process of production thereof
US9393205B2 (en) Gastroretentive tablets
RU2010119463A (ru) Двухслойная композиция для непрерывного высвобождения ацетаминофена и трамадола
MX2013014461A (es) Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas.
MX2012008413A (es) Composicion novedosa de retigabina.
MY157187A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
PH12013500173A1 (en) Oral controlled release pharmaceutical compositions of blonanserin
CA2794655A1 (en) Method for treating schizophrenia and related diseases
NZ591408A (en) Paracetamol and Calcium carbonate composition
IN2015DN01738A (enExample)
MX2013003523A (es) Composicion farmaceutica de dosis baja.
MY204440A (en) Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition
EA201070625A1 (ru) Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества
Chen et al. Preoperative low-dose and high-dose pregabalin and cardiovascular response to endotracheal intubation: a prospective, randomized, single-blind, controlled study in China
WO2011080570A8 (en) Extended release pharmaceutical composition comprising linezolid and process for preparing the same

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 JUL 2016 BY HENRY HUGHES

Effective date: 20130503

LAPS Patent lapsed